Pharmacogenomics and perioperative medicine - Implications for modern clinical practice;Pharmacogénomique et médecine périopératoire: Implications pour la pratique clinique moderne

Canadian Journal of Anesthesia

Volumn 55, Issue 12, 2008, Pages 799-806

  Kim, Jerry H ^a   Schwinn, Debra A ^a   Landau, Ruth ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CODEINE; CYTOCHROME P450 2D6; DESFLURANE; FENTANYL; INHALATION ANESTHETIC AGENT; ISONIAZID; LIDOCAINE; MORPHINE; MU OPIATE RECEPTOR; OPIATE; PRIMAQUINE; SALBUTAMOL; SUXAMETHONIUM; WARFARIN;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; ANALGESIA; ANESTHESIST; ANTICOAGULATION; ASTHMA; BRONCHODILATATION; CHROMOSOME 19Q; CHROMOSOME 3Q; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFICACY; DRUG METABOLISM; EDITORIAL; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRAIT; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HEART PROTECTION; HUMAN; INHERITANCE; KERNEL METHOD; MALIGNANT HYPERTHERMIA; MUSCLE METABOLISM; NAUSEA; NOCICEPTION; OBSTETRIC ANALGESIA; PAIN; PATIENT SAFETY; PERIOPERATIVE PERIOD; PHARMACOGENETICS; PHARMACOGENOMICS; PREOPERATIVE EVALUATION; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VOMITING;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANALGESIA, OBSTETRICAL; ANALGESICS, OPIOID; ANESTHESIOLOGY; ANESTHETICS, GENERAL; ANTICOAGULANTS; ASTHMA; DRUG TOXICITY; GENETIC VARIATION; HUMANS; MALIGNANT HYPERTHERMIA; MYOCARDIAL INFARCTION; NEUROMUSCULAR DEPOLARIZING AGENTS; PAIN, POSTOPERATIVE; PERIOPERATIVE CARE; PHARMACOGENETICS; PHYSICIAN'S PRACTICE PATTERNS; SUCCINYLCHOLINE; WARFARIN;

EID: 57349134460     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03034050     Document Type: Editorial

References (21)

1. Kalow W. The relation of plasma cholinesterases to response to clinical doses of succinylcholine. Can Anaesth Soc J 1956; 3: 22-30.
2. Kalow W. Pharmacogenetics, Heredity and the Response to Drugs. Philadelphia: W.B. Saunders; 1962.
3. Budnitz D, Shehab N, Kegler S, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147: 755-65.
4. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7: 99-111.
5. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
6. Andersen SS, Hansen ML, Gislason GH, et al. Mortality and reinfarction among patients using different beta-blockers for secondary prevention after a myocardial infarction. Cardiology 2008; 112: 144-50.
7. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005; 294: 1526-33.
8. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505-12.
9. Wechsler ME, Lehman E, Lazarus SC, et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173: 519-26.
10. Hawkins GA, Weiss ST, Bleecker ER. Clinical consequences of ADRbeta2 polymorphisms. Pharmacogenomics 2008; 9: 349-58.
11. Kalow W. Familial incidence of low pseudocholinesterase level. The Lancet 1956; 271: 2.
12. Kalow W, Genest K. A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers. Can J Biochem Physiol 1957; 35: 339-46.
13. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis 2007; 2: 21.
14. Liem EB, Lin CM, Suleman MI, et al. Anesthetic requirement is increased in redheads. Anesthesiology 2004; 101: 279-83.
15. Liem EB, Joiner TV, Tsueda K, Sessler DI. Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficacy in redheads. Anesthesiology 2005; 102: 509-14.
16. Mogil JS, Wilson SG, Chesler EJ, et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA 2003; 100: 4867-72.
17. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain 2008; 139: 5-14.
18. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95: 9608-13.
19. Caraco Y. Genes and the response to drugs. N Engl J Med 2004; 351: 2867-9.
20. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351: 2827-31.
21. Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 2006; 102: 146-50.